Hologic, Inc. Overview
Pro stress-test →Hologic develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide, operating through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company is in transition, with a definitive agreement to be acquired by funds managed by Blackstone and TPG for $76 per share in cash plus a non-tradable contingent value right (CVR) of up to $3 per share.
Strategic Profile
Pro stress-test →Hologic has always thrived on innovations, with the FDA-approved 3DQuorum Imaging Technology representing the first of several products powered by the company's core AI platform, Genius AI. The company benefits from recurring revenue streams through service contracts for its installed base, though recent quarters have faced margin pressure with a 13.2% net profit margin compared with 18.4% in the prior year.
Competitive Landscape
Pro stress-test →Hologic competes in breast cancer care through 3D digital mammography systems, image analysis software, and minimally invasive biopsy guidance systems, facing competition from larger medtech players in diagnostics, imaging, and surgical platforms. Key competitors include Siemens Healthineers, GE Healthcare, Intuitive Surgical, and Roche in various segments, with differentiation through AI-driven innovation and women's health focus.
Industry Context
Hologic, Inc. operates in Medical Devices & Diagnostics - Women's Health Focus.
Key facts
Headquarters: Marlborough, Massachusetts, US · Revenue: $4.1B (trailing 12 months) · Market cap: $18.3B (pending Blackstone-TPG acquisition)